We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Check the tariff classification for flavour pods.
How the maritime industry should treat waste at sea and in ports, reduce oil and air pollution, and control ozone-depleting substances.
Diagnosis and epidemiology of Mycoplasma pneumoniae.
The signs of foot and mouth disease, what to do if you suspect it in your animals and measures to prevent its spread.
Information for clinicians on the characteristics, diagnosis and epidemiology of infections caused by Chlamydia psittaci.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Find out about the long-term effects some people can have after having COVID-19.
Paper prepared by Kings College London (KCL) on the loss of smell and taste with COVID-19.
Get help to classify cigarettes, cigars, raw tobacco, smoking tobacco, tobacco for heating and nicotine substitutes for import and export.
How to spot and report bee pests and diseases.
Background information and advice on coronavirus (COVID-19) for health and care professionals.
Information for clinicians on diagnosis and notification of Shiga toxin-producing Escherichia coli (STEC) and haemolytic uraemic syndrome (HUS).
Batches of some products made by Legency Remedies Pvt Ltd have been found to contain a bacteria called Ralstonia pickettii (R. pickettii). All potentially affected batches are being recalled following an MHRA investigation.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.
Substances that are classed as persistent organic pollutants (POPs) and when you're allowed to use them.
Public health principles for reducing the spread of respiratory infections, including COVID-19, in the workplace.
Clinicians are provided with actions to complete when managing infectious diseases in the asylum seeker population.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.